Ascentage Pharma Group International (NASDAQ:AAPG) Issues Earnings Results

Ascentage Pharma Group International (NASDAQ:AAPG) issued its quarterly earnings results on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, reports. The business had revenue of $22.24 million for the quarter.

Ascentage Pharma Group International Stock Down 3.9%

Shares of AAPG stock opened at $17.32 on Friday. Ascentage Pharma Group International has a twelve month low of $16.36 and a twelve month high of $48.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The business has a fifty day simple moving average of $18.21 and a 200 day simple moving average of $21.23.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG grew its stake in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the 2nd quarter worth $391,000. Finally, Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the 3rd quarter worth about $383,000.

Analysts Set New Price Targets

Several research analysts recently commented on the company. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.